The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy
Abstract Background Salivary gland carcinomas (SGC) are extremely rare malignancies with only limited treatment options for the metastatic phase of the disease. Treatment with anti-CD47 antibodies could represent a potent therapy for SGCs by promoting the phagocytic clearance of tumor cells through...
Main Authors: | Michal Votava, Robin Bartolini, Linda Capkova, Jitka Smetanova, Vachtenheim Jiri, Martin Kuchar, David Kalfert, Jan Plzak, Jirina Bartunkova, Zuzana Strizova |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-09-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-022-10114-4 |
Similar Items
-
YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells
by: Anna Josefine von Ofen, et al.
Published: (2024-01-01) -
Is CD47 an innate immune checkpoint for tumor evasion?
by: Xiaojuan Liu, et al.
Published: (2017-01-01) -
Monocytes engineered with iSNAP inhibit human B‐lymphoma progression
by: Haohsiang Wu, et al.
Published: (2022-05-01) -
Don't eat me/eat me signals as a novel strategy in cancer immunotherapy
by: Amirreza Khalaji, et al.
Published: (2023-10-01) -
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity
by: Ewa Cendrowicz, et al.
Published: (2022-03-01)